Herceptin Hylecta® (trastuzumab and hyaluronidase-oysk)
for Breast Cancer

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) is a targeted immunotherapy used to treat HER2-positive breast cancer. It combines trastuzumab, a monoclonal antibody that blocks the HER2 protein to slow cancer growth, with hyaluronidase to enhance absorption under the skin. Herceptin Hylecta works by stopping cancer cell division and triggering the immune system to attack HER2-positive cancer cells through antibody-dependent cell-mediated cytotoxicity (ADCC).

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Breast Cancer